Galapagos NV (ADR) (GLPG) is Upgraded by Goldman to Buy

Galapagos NV (ADR) (GLPG) was Upgraded by Goldman to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on Oct 18, 2016.

Galapagos NV (ADR) closed down -0.13 points or -0.20% at $64.12 with 1,13,566 shares getting traded on Friday. Post opening the session at $65.33, the shares hit an intraday low of $63.8 and an intraday high of $65.48 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations encompassing target discovery and validation screening and drug discovery through to delivery of pre-clinical candidates. As of December 31 2011 Galapagos NV was through its subsidiaries active in Belgium France Switzerland the Netherlands the United Kingdom Germany the United States and Croatia. In April 2014 it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Galapagos NV (ADR)

Leave a Reply

Galapagos NV (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Galapagos NV (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.